

## Occurrence of venlafaxine residues and its metabolites in marine mussels at trace levels: development of analytical method and a monitoring program

M. J. Martínez Bueno<sup>1,\*</sup>, C. Boillot<sup>1</sup>, D. Munaron<sup>2</sup>, H. Fenet<sup>1</sup>, C. Casellas<sup>1</sup>, E. Gómez<sup>1</sup>

<sup>1</sup> Hydrosiences Montpellier UMR 5569, Department of Environmental Sciences and Public Health, University of Montpellier, I, 34000, Montpellier, France

<sup>2</sup> IFREMER, Environment Resources Laboratories of the Languedoc-Roussillon, 34203, Sete, France

\*: Corresponding author : M. J. Martínez Bueno, email address : [mjbueno@ual.es](mailto:mjbueno@ual.es)


### Abstract:

Coastal areas are subject to growing pressures and impacts because of the increase in human activities. Lipophilic organic contaminants, such as polycyclic aromatic hydrocarbons (PAHs) or polychlorinated biphenyls (PCBs), have been monitored for decades within monitoring programs. However, until now, little information on the detection of so-called “emerging contaminants” such as hydrophilic organic compounds in the marine environment and no data on its metabolites or transformation products in marine organisms is available. In this report, a sensitive analytical methodology for identification and confirmation of venlafaxine (VEN) residues and five of its main metabolites in the marine mussels *Mytilus galloprovincialis* was validated. The sample preparation procedure was based on the Quick, Easy, Cheap, Effective, Rugged, and Safe (QuEChERS) approach. An analytical method was developed to quantify these compounds at trace levels by liquid chromatography coupled to high-resolution mass spectrometry. The method was then applied to marine mussels collected from the Mediterranean Sea in southeastern France. Residues of the antidepressant VEN were occasionally detected at ng/g dw level. In addition, the approach allowed us to identify several transformation products in the analyzed samples. *N*-desmethylvenlafaxine (NDV) was the most frequently detected metabolite followed by *N,O*-desmethylvenlafaxine (NODDV).

**Keywords:** Antidepressant ; Emerging contaminants ; Transformation products ; Marine organisms ; Orbitrap ; QuEChERS

### Graphical abstract

Occurrence of venlafaxine residues and its metabolites in marine mussels



## 43 1. Introduction

44 Public interest regarding the presence of pharmaceuticals in the environment is mounting.<sup>1</sup> In  
45 Europe, around 3000 different pharmaceutical active compounds, used as human and  
46 veterinary drugs are susceptible to reach every environmental compartment. Coastal areas are  
47 subject to growing pressures and impacts due to increasing of the human activities. In view of  
48 serious threats to the European coasts, the European Parliament and the Council approved  
49 Recommendation 2002/413/CE concerning the implementation of Integrated Coastal Zone  
50 Management in Europe in order to improve the water quality.<sup>2</sup>

51 Venlafaxine (VEN) is an antidepressant drug prescribed for the treatment of clinical  
52 depression and anxiety disorders. It is one of the most commonly prescribed classes of  
53 pharmaceuticals in the world. Approximately, 29% of a VEN applied dose is excreted in the  
54 urine within 48 hours as the unconjugated metabolite O-desmethylvenlafaxine (ODV) while  
55 only 5% of the amount is excreted as unchanged parent compound.<sup>3</sup> Some publications have  
56 reported that maternal exposure to this antidepressant elevates fetal plasma serotonin levels,  
57 which has been associated with autism and increased risk of spontaneous abortion.<sup>4</sup> Regarding  
58 its aquatic fate, recent studies have indicated the presence of VEN in wastewater effluent,<sup>5-7</sup>  
59 surface water<sup>8-10</sup> and even drinking water.<sup>11</sup> About the detection of its transformation  
60 products in the environment, Lajaunesse *et al.*<sup>6</sup> reported, for the first time, the occurrence of  
61 ODV in Canadian municipal wastewater ranged from 21-68 ng/L. More recently, it has been  
62 identified in effluents from waste water treatment plants (WWTPs) and surface waters in  
63 Germany, at concentrations up to 500 ng/L and 743 ng/L, respectively.<sup>7,12</sup> The removal rates  
64 published for both compounds in the conventional wastewater treatment plants are about  
65 40%.<sup>9</sup> However, to our knowledge no data exist regarding presence of such substances in  
66 coastal marine waters. This issue can be partly explained by sampling complexity and the lack  
67 of suitable analytical methodologies in those environmental compartments where higher  
68 sensitivity is required due to higher dilution rates.<sup>13</sup> Traditional sampling techniques using  
69 discrete water sampling are not very performing to such purpose. On the other hand, the  
70 present generation of passive samplers enables detection of micro-organic contaminants at  
71 low concentrations. Nevertheless, some authors have suggested that passive samplers must  
72 still be further developed and validated, *in situ*, since laboratory conditions generally differ  
73 too greatly from those in the field.<sup>14,15</sup>

74 To overcome this lack, the use of marine organisms as a tool for the biomonitoring of a  
75 pharmaceutical and its transformation products in marine environments was evaluated in the  
76 present study. Mediterranean mussel (*M. galloprovincialis*) is a common filter feeder widely  
77 distributed in sea coasts. According to the claims of some authors, this species is an excellent  
78 sentinel for monitoring of organic micro-pollutants, because it can bioaccumulate substances  
79 through their gills (dissolved substances) and/or digestive tract (substances sorbed on  
80 particles).<sup>16,17</sup> Then again, an estimated bioconcentration factor (BCF) of 60 suggests a  
81 moderate potential for bioconcentration in aquatic organisms for the case of VEN.<sup>18</sup> But up to  
82 date, the few studies of the presence of antidepressants in aquatic organisms outside the  
83 laboratory have focused on fluoxetine, sertraline, serotonine or norfluoxetine. Such research  
84 showed that these substances were present in fish sampled from effluent-impacted rivers.<sup>8,19,20</sup>  
85 Little information on the detection of VEN and its metabolites in aquatic organisms and no  
86 data in marine organisms are available in literature.

87 In view of that, the objectives of this study were: (i) to develop and validate a simple, rapid  
88 and sensitive analytical approach for detection, characterization and quantification of  
89 venlafaxine residues and five of its main metabolites in marine mussels. For that, an easy  
90 QuEChERS extraction method combined with liquid chromatography mass spectrometry  
91 system (LC-Orbitrap-MS) was the procedure validated and described in this study. Accurate  
92 mass measurements in MS and MS/MS modes were performed in the same run, which are  
93 highly useful for the identification of isomeric compounds, a common problem when several  
94 transformation products are analyzed. The more demanding requirements regarding mass  
95 spectrometric confirmation currently set by EU regulations (Commission Decision  
96 2002/657/EC and SANCO/10684/2009 Guideline) were taken into account.<sup>21,22</sup> Therefore, a  
97 total of 5 identification points were obtained for each analyte, limiting the number of false  
98 positive results in order to achieve suitable identifications. (ii) To evaluate the use of marine  
99 organisms as a tool for biomonitoring of hydrophilic organic compounds in aquatic  
100 environments and (iii) to demonstrate the utility of the method by providing new results on  
101 the contamination of French coastal areas by emerging contaminants, as well as by their  
102 transformation products.

## 103 **2. Experimental**

### 104 **2.1. Chemicals and reagents**

105 The structure and physiochemical properties of target analytes are listed in [Table 1](#). N,N-  
106 Didesmethyl-O-desmethylvenlafaxine (NNDDODV), N,O-Di-Desmethylvenlafaxine  
107 (NODDV), O-Desmethylvenlafaxine (ODV), N-Desmethylvenlafaxine (NDV), N,N-  
108 Didesmethylvenlafaxine (NNDDV) and venlafaxine-d6 (VEN-d6) were purchased at  
109 analytical grade (purity > 90%) from Toronto Research Chemicals Inc (Ontario, Canada),  
110 except venlafaxine (VEN), which was obtained from Sigma–Aldrich (Steinheim, Germany).  
111 Stock standard solutions of individual compounds were prepared at a concentration of 1mg/ml  
112 in methanol. All the standard solutions were stored at –20°C.

113 Ultrapure water, methanol (MeOH) and HPLC-grade acetonitrile (AcN) were supplied by  
114 Carlo Erba (Val de Reuil, France). Formic acid (purity, 98%) was obtained from Fisher  
115 Labosi (Elancourt, France). QuEChERS material: sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>) anhydrous and  
116 sodium chloride (NaCl) were obtained from Carlo Erba (Val de Reuil, France). Sodium citrate  
117 dihydrate (Na<sub>3</sub>Cit:2H<sub>2</sub>O) and sodium citrate dibasic sesquihydrate (Na<sub>2</sub>HCit:3H<sub>2</sub>O) were  
118 purchased by Sigma–Aldrich (St. Louis, MO, USA). Dispersive SPE tubes containing Z-Sep-  
119 Plus (500 mg/12 mL) and primary secondary amine (PSA) sorbent were obtained from  
120 Supelco (Bellefonte, PA, USA) and C-18 (40 µm particle size) from Varian (Palo alto, CA,  
121 USA), respectively. Calibration mixture for mass spectrometer comprised the following:  
122 MSCAL5-IEA (caffeine, tetrapeptide “Met-Arg-Phe-Ala”, ultramark was purchased from  
123 SUPELCO (Bellefonte, PA, USA).

## 124 **2.2. Samples and sample preparation**

125 Marine mussels were collected from different zones of the Mediterranean Sea located in  
126 southeaster France (Frontignan, Montpellier and Marseille). Samples (n= 23) were collected  
127 from production cultures, an important lagoon (with substantial harbour activity and very  
128 influenced by human settlements) and in the vicinity of a submarine outfall (industrial/urban  
129 discharges). In order to monitor the fluctuations in the occurrence of target compounds due to  
130 localization variation, one additional campaign was performed from samples collected in  
131 Marseille (n=7) in the vicinity of a marine outfall. Moreover, some mussel samples were  
132 randomly purchased in different local markets (n=4) in the Montpellier area. So, a total of 34  
133 samples were analyzed in different biomonitoring programs performed from 2011 to 2013.  
134 Mussels of 4-5 cm long were cleaned of sedimentary material, epiphytes and epifauna,  
135 washed and then the flesh was separated from the shell. Samples were then stored at –20°C  
136 until their treatment. Mussels were freeze-dried (Heto Power dry LL 3000, Thermo),

137 homogenized and grounded into powder using MM-2 vibrational mill (Retsch, Haan,  
138 Germany). Each sample were then placed inside a clean and opaque glass bottle and stored in  
139 dark until extraction and analysis.

#### 140 *2.2.1. Sample extraction*

141 Sample preparation was based on extraction with water and acetonitrile with subsequent salt-  
142 induced phase partitioning. The procedure used is a modification of a previously reported  
143 method for the determination of carbamazepine in marine mussel, developed by our team.<sup>23</sup>  
144 Briefly, sample treatment by QuEChER approach was based on 2 g  $\pm$  0.01 freeze-dried  
145 mussels were weighed in a 50 mL polypropylene centrifuge tube and spike with surrogate  
146 standard (VEN-d6). Next, the mussels were rehydrated by adding 10 mL of ultrapure water.  
147 The tubes were then manually and vigorously shaken for 2 min, after the addition 10 mL of  
148 AcN. Then QuEChERS salts (4 g Na<sub>2</sub>SO<sub>4</sub> (anh), 1 g NaCl, 1 g Na<sub>3</sub>Cit:2H<sub>2</sub>O and 0.5 g  
149 Na<sub>2</sub>HCit:3H<sub>2</sub>O) were added and the mixture was immediately vigorously shaken (manually)  
150 for 1 min more. After the centrifugation step (3500 rpm, 5 min), 2.5 mL of the upper AcN  
151 layer was transferred into a Z-Sep-plus tube and 50  $\mu$ L of formic acid was added and shaken  
152 for 1 min. 1 mL of mixture was evaporated to dryness. The residue was reconstituted in 1 mL  
153 of AcN/water (1:9, v/v). Finally, the sample was centrifuged at 10,000 rpm for 10 min to  
154 separate the residual lipids and the extract was filtered directly into an analysis vial using a  
155 0.45  $\mu$ m PTEF syringe filter.

#### 156 **2.3 LC–MS analysis**

157 The separation of the analytes was carried out using an HPLC (Accela 1250 Pump and a  
158 degasser, Thermo Scientific, USA) equipped with a C18 analytical column, 100 mm length x  
159 2.1 mm I.D and 1.8  $\mu$ m particle size (ZORBAX XDB, Agilent Technologies). The LC mobile  
160 phases were AcN (A) and water (B) both containing 0.1% formic acid. The optimal separation  
161 was achieved using a 200  $\mu$ L/min flow rate and the following gradient: 1 min isocratic at 10%  
162 A, then a linear gradient to 100 % A at 8 min, and finally 5 min isocratic at 100 % A. After  
163 that, 7 min of post-time followed using the initial 10 % of A. The volume of injection was 10  
164  $\mu$ L.

165 For analysis, an Exactive mass spectrometer (Thermo Fisher Scientific, USA) system  
166 equipped with a heated electrospray ionization probe (HESI) source in positive ion mode was  
167 used. The HESI parameters were: electrospray voltage, 4.0 kV; sheath gas, 35 arbitrary units;  
168 auxiliary gas, 10 arbitrary units. The heater in the source was set to 200 °C and the heated

169 capillary in the mass spectrometer was operated at 300 °C. Data were acquired by  
170 continuously alternating full MS and MS/MS modes: one without and one with fragmentation  
171 (both  $m/z$  150-350). For fragmentation, an additional experiment using a higher-energy  
172 collisional dissociation (HCD) cell fixed at 15 eV, was included in the run. The resolving  
173 power for both scan events was 50,000 FWHM at 0.25 s for each one. The automatic gain  
174 control (AGC) target was set to  $1 \times 10^6$  ions (balance scan). All the other parameters for the  
175 mass spectrometer (tube lens, skimmer and capillary voltage) were automatically tuned to  
176 obtain the highest TIC signal. The final values were 70, 16 and 65 V, respectively.  
177 Confirmation of each compound was performed by means of (i) retention times, (ii) mass  
178 accuracy  $< 5$  ppm in full scan MS of protonated molecule  $[M+H]$  and (iii) the acquisition of at  
179 least one fragment ion together a mass accuracy  $< 5$  ppm in full scan MS/MS. The second  
180 diagnostic ion should be sensitive and selective, with a variation of the abundance relative  
181 within a certain range.<sup>22</sup> Figure 1 show the extracted ion chromatogram (XIC) and product ion  
182 mass spectrum obtained in MS and MS/MS mode, of the protonated target compounds using  
183 fragmentation energy of 15 eV for a mussel sample spiked at 1 ng/g.

#### 184 2.4. Method validation

185 A rigorous validation procedure according to SANCO/10684/2009 and ISO/17025 Guidelines  
186 was performed to ensure high quality analytical measurements.<sup>22,24</sup> Method accuracy and  
187 precision were evaluated by recovery studies using blank mussels samples spiked at two  
188 concentration levels 5 and 50 ng/g dw. All experiments were tested with six replicates, in  
189 accordance with the recommendations of EU guidelines before cited. Quantitation of the  
190 compounds in the spiked samples was carried out comparing the peak areas of the samples  
191 with those of matrix matched standard solutions. These, as well as the matrix-matched  
192 calibration curves, were prepared by spiking an aliquot of the blank extract with the desired  
193 amount of standard solution. The sensitivity of the method was calculated in terms of limit of  
194 quantitation (LOQ) and limits of detection (LOD), which were calculated as the minimum  
195 concentration of analyte that generated a signal to noise (S/N) ratio of 10 and 3, respectively,  
196 from signal obtained to matrix-matched calibration curves. Linearity was evaluated both in  
197 solvent and matrix, using matrix-matched calibration curves prepared as described before, in a  
198 concentration range of 0.1–10 ng/g. The matrix effect was studied by comparison of the  
199 slopes of the calibration curves in solvent and in matrix. The repeatability of the instrumental  
200 method was estimated by determining the inter- and intra-day relative standard deviation

201 (R.S.D, %) by the repeated analysis ( $n = 5$ ) of a spiked matrix extract at 1 ng/g, from run-to-  
202 run over one day and five days, respectively.

203 Finally, in order to ensure quality measurements, each day before analysis, the calibration of  
204 Exactive mass spectrometer was performed using the calibration mixture. After that, a  
205 standard mixture (10 ng/L) containing targeted analytes was injected with the purpose to  
206 check the performance of the HPLC, analytical column and Orbitrap MS system. A  
207 continuous monitoring of the quality of the analytical procedure was carried out through the  
208 inclusion of blank (solvent) during the day-work sequence.

### 209 **3. Results and discussion**

#### 210 **3.1. Method validation results**

211 The more demanding requirements regarding mass spectrometric confirmation currently set  
212 by EU regulations were taken into account for confirmation and quantification of each target  
213 compounds. Commission Decision 2002/657/EC<sup>21</sup> describes a system of identification to  
214 obtain a minimum of four identification points, in which, detection of transition products in  
215 HR-MS<sup>n</sup> yields two identification points per ion. SANCO/10684/2009 Guideline<sup>22</sup>  
216 recommended the acquisition of  $\geq 2$  diagnostic ions (preferably including the quasi molecular  
217 ion and at least one fragment ion) and a mass accuracy  $< 5$  ppm. In this way, the obtention of  
218 one exact precursor ion and one exact product ion, and along with the retention time, allowed  
219 us obtained a total of 5 identification points per each compound, as identification criteria in  
220 this study. Therefore, the issue of false positive results for analytical methods at ultra-trace  
221 levels in which analyte detection is based on retention time and only one exact mass was  
222 resolved.

##### 223 *3.3.1. Recoveries*

224 The accuracy of the method was verified by measuring recoveries from blank mussel spiked  
225 with 5 and 50 ng/g dw of each chemical. These levels would imply 1 and 10 ng/g, in the final  
226 extract. All experiments were performed by six fold for each matrix. The mean recovery data  
227 and deviations obtained, which highlights the precision of the extraction method, are given in  
228 [Table 2](#). Mussels are fat or lipid containing matrices (about 15%) and, although fats are not  
229 very soluble in AcN, a certain quantity of them will be co-extracted, so they have to be  
230 removed prior to the final determination step.<sup>23</sup> For that, a new sorbent material Z-Sep-plus  
231 used to enhance matrix interference removal was evaluated in this study. They contain

232 zirconium atoms, which act as a Lewis acid, while the phosphate groups in phospholipids act  
233 as a strong Lewis base, strongly binding with zirconium atoms. According to the  
234 manufacture's specifications these sorbents can significantly remove fatty matrix interferences  
235 and color from sample extracts, provides more robust LC/MS methods. Satisfactory  
236 recoveries for all selected compounds were achieved by developed QuEChERS approach. The  
237 average recovery values for both spike levels were higher than 70%, except to metabolite  
238 NNDDV (61%) and NNDDODV (55%) at 5 ng/g level. Finally, highlight the importance of  
239 the addition of formic acid. Many sample preparation techniques for biological matrices use  
240 acid to disrupt compound-protein binding, which directly affects recovery and matrix effect.<sup>23</sup>  
241 Thus, the addition of 2% formic acid was a critical step. In the absence of this additive,  
242 recoveries were reduced to more than half (<30%, data not included).

### 243 3.3.2. Linearity and matrix effect

244 The linearity of the analytical response was evaluated using solvent and matrix-matched  
245 calibration curves at five concentration levels covering three orders of magnitude: from 0.1–  
246 10 ng/g, based on linear regression and squared correlation coefficient ( $r^2$ ). All the studied  
247 compounds presented a very good response of three orders of magnitude, with correlation  
248 coefficients higher than 0.997 in all cases.

249 Matrix effect was also evaluated during the validation of the method. In fact, signal  
250 suppression or enhancement can severely compromise quantitative analysis of the compounds  
251 at trace levels, as well as affect the method reproducibility and accuracy.<sup>25</sup> The matrix effect  
252 was studied by comparison of the slopes of the calibration curves in solvent and in matrix.  
253 When the percentage of the difference between these slopes is positive, then there is signal  
254 enhancement, whereas a negative value indicates signal suppression.. According to our results  
255 (Table 2), five compounds showed no matrix effect (<20%, because this variation is close to  
256 the repeatability values), and only two metabolites, NODDV and ODV, presented a medium  
257 effect (<31%). In spite of these low values, matrix-matched calibration curves were used to  
258 compensate the matrix effect and avoid any under/over estimation during the quantification.

### 259 3.3.3. Precision

260 In order to evaluate the repeatability of the instrumental method, the intra- and inter-day  
261 R.S.D were studied. Method repeatability was determined at 10 ng/g, by the analysis of five  
262 spiked matrix extracts . R.S.D values for intra-day (repeatability) ranged between 1% and 6%.



263 The reproducibility (inter-day) was calculated during five consecutive days, and it varied from  
264 3% to 14% (see [Table 2](#)). This demonstrates the repeatability of the method and therefore its  
265 effectiveness for quantitative purposes.

#### 266 3.3.4. Sensitivity

267 The sensitivity of the method was calculated in terms of limit of quantitation (LOQ)  
268 and detection (LOD), which were estimated as the minimum concentration of analyte that  
269 generated a S/N of 10 and 3, respectively, from signal obtained to matrix-matched calibration  
270 curves. The reporting levels of the studied compounds range from 0.1 to 0.3 ng/g (LOD) and  
271 0.5 to 0.8 ng/g (LOQ) (see [Table 2](#)). However, method detection limits (MDLs, ng/g dw) and  
272 method quantification limits (MQLs, ng/g dw) are more appropriate for establishing  
273 environmental analysis detection thresholds because they take the dilution or pre-  
274 concentration steps during sample preparation into account. As shown in [Table 2](#), MDLs  
275 values (0.5 to 1.5 ng/g) were typically higher than any of the LOD data (0.1 to 0.3 ng/g), since  
276 a 5-fold dilution step is applied to the sample. Nevertheless, the developed analytical method  
277 allowed determination of the target analytes at concentration levels the order of a few ng/g dw  
278 in mussels exposed in marine water.

#### 279 3.3.5. Specificity and selectivity

280 The specificity of the method was assessed through the analysis of three blank mussel  
281 samples extracted by the optimized QuEChERS methodology. No other significant peaks  
282 ( $S/N \geq 3$ ) were found at the specific retention times of target pharmaceuticals. On the other  
283 hand, in full scan mass spectrometry measurements, selectivity is obtained by creation of  
284 extracted ion chromatograms (EICs) of quasimolecular ions of the compounds of interest. The  
285 use of HRMS enables data analysis using the EICs with a narrow mass-extraction window,  
286 which provides the required selectivity.<sup>26</sup> The retention times were together the accurate mass,  
287 the criteria established to carry out the identification of analytes in samples, taking into  
288 account a maximum mass deviation of 5 ppm and considering chromatographic peak with  $S/N$   
289  $\geq 3$ . Furthermore, an additional scans for the unambiguous identification of the target  
290 compounds present in the samples, via spectral acquisition with HCD fragmentation at 15 eV  
291 were included in the analytical method. Therefore, two chromatograms are collected, one  
292 containing full-scan mass for non-fragmented ions and other more for MS/MS data, which  
293 containing information about the fragmented ions obtained at this collision energy.

### 294 3.4. Analysis of real samples

295 The applicability of the proposed method was assessed for the analysis of marine mussel  
296 samples, collected from different areas of the Mediterranean Sea located in southeaster France  
297 and local supermarkets in Montpellier (France). Analytes detection was based on extraction of  
298 the exact mass (< 5ppm) of the precursor ion at the correct retention time ( $\pm 30$  s) and the  
299 presence of almost one second product ion. All these identification criteria were compared to  
300 those obtained with matrix-matched calibration curves in the same batch, according to the  
301 recommendations established by Commission Decision 2002/657/EC<sup>21</sup>. Venlafaxine and its  
302 transformation products were detected in mussel samples during the biomonitoring program  
303 performed from January 2011 to 2013. With regard to EU surface waters, their occurrence has  
304 been reported at concentrations ranging from some ng/L to 1  $\mu\text{g/L}$ .<sup>10-12</sup> In contrast, no studies  
305 in coastal waters or marine organisms have previously been reported for such compounds up  
306 to date. Residues of the selected antidepressant drug (VEN) were occasionally detected in  
307 four marine mussel samples, but it was only found in one at concentration above its MQL (2.5  
308 ng/g dw). However, several transformation products were detected at higher levels. N-  
309 Desmethylvenlafaxine (NDV) was the most frequently identified metabolite followed by N,O-  
310 Di-Desmethylvenlafaxine (NODDV) and O-Desmethylvenlafaxine (ODV) at levels up to 3.0,  
311 3.5 and 3.7 ng/g dw, respectively. All the results obtained are summarized in [Table 3](#).

312 Several studies have reported higher concentrations of ODV than VEN in treated wastewater  
313 and surface water, with a mean ratio of approximately 5:1.<sup>7</sup> The same ratio was observed by  
314 Nakamura *et al.*<sup>27</sup> in fish (*Oryzias latipes*) exposed to antidepressant fluoxetine. Such  
315 research showed that its metabolite (norfluoxetine) presented concentrations five times greater  
316 than fluoxetine levels. However, in lack of bioaccumulation experiments that allow us to  
317 justify the hypothesis of the VEN metabolism in mussels, it is difficult to determine whether  
318 the metabolites were present in the mussels as a result of the metabolization of the organism, or  
319 as a result of direct uptake from water. In any event, as it has previously been discussed by  
320 other scientific, the metabolite profile varied significantly among species. ODV is the major  
321 metabolite in humans, but not in mouse, rat, dog, or monkey.<sup>28</sup> Therefore, it is not appropriate  
322 to assume the same metabolic reactions in mussels and in human. In any case, our results are  
323 in agreement with other studies. Metcalfe *et al.*<sup>9</sup> observed residues of VEN and NDV at mean  
324 concentrations of 1.2 and 2.18  $\mu\text{g/kg}$  wet weight in caged fish muscle collected downstream  
325 of a WWTP in Canada. In this study, ODV was also detected, but at levels below its limits of  
326 quantification (0.5  $\mu\text{g/kg}$  ww). In 2013, a recent work reports the occurrence of 17

327 pharmaceuticals and personal care products (PPCPs) and 3 alkylphenols (APs) in benthic  
328 mussels (*Geukensia demissa*) collected from an urban estuary (San Francisco Bay, USA).<sup>29</sup> In  
329 this study, similar concentrations to ours were found for other antidepressant (sertraline), up  
330 to 1.4 ng/g ww using 5.5 g of wet tissue. However, the levels of PPCPs were generally at least  
331 an order of magnitude lower than levels of APs.

332 Any analyte was detected in samples purchased from different local supermarkets in France  
333 (n=4) nor in mussel samples taken from the production cultures or reference zone (n=4).  
334 Finally, only one metabolite (NNDDODV) was not detected in samples from our  
335 biomonitoring program. In any case, the recovery of the surrogate standards was above 75%  
336 for each analyzed sample. It standards allowed us to verify that extraction method  
337 performance and analysis were satisfactory. An example of identification of a sub-product of  
338 VEN in a marine mussel sample is presented in [Figure 2](#). In full MS spectrum, the measured  
339 mass for NNDDV is shown at  $m/z$  250.17879 which matches the theoretical mass 250.1801  
340 with an error of -3.6 ppm. The additional acquisition in full MS/MS mode provided a more  
341 comprehensive identification of this compound as well as its structural characterization found  
342 for the characteristic fragment ion at  $m/z$  201.12748 with a mass deviation of -2.30 ppm.  
343 Good mass accuracies were obtained both in the MS and MS/MS scans (< 5ppm). Thus, a  
344 correct identification was ensured in line with the other evaluated parameter (retention time,  
345 tr).

346 To conclude, the results support the hypothesis of a moderate bioconcentration for VEN in  
347 aquatic organisms, despite of its modest octanol-water partition coefficient  $K_{ow}$  3.28.<sup>7,30</sup>  
348 Bioconcentration factors are often described as being associated with the lipophily of the  
349 molecule. However, in line with previous studies, the accumulation not always increased with  
350 a linear relation, suggesting other bioconcentration mechanisms such as the  
351 biotransformation. Gómez *et al.*<sup>16</sup> explained these differences by possible clearance  
352 mechanisms/metabolization in marine mussels. Thus, although the initial results were  
353 positive, future experiments should be conducted on the bioaccumulation of VEN and its  
354 metabolites in marine mussels in order to assess their bioconcentration factors and therefore  
355 obtained data regarding its distribution and persistence in marine aquatic organisms. Also, this  
356 data will be useful in retrospective ecological risk assessments to support an understanding of  
357 environmental exposure as well as for predicting toxic effects in marine organisms.

358 *3.4.1. Spatial-temporal variation*

359 In order to monitor the fluctuations in the occurrence of target compounds in study area, a  
360 seasonal and monthly variation were also evaluated (see results [Table 3](#)). As can see, a greater  
361 number of analytes were identified in the sample collected at east points in the vicinity of a  
362 submarine outfall, during the first months of the year (January to April). This may be due to  
363 two hypotheses: (i) differences in ocean currents or (ii) a possible increase in the consumption  
364 of this type of drugs to treat disorders related to depression during those months. Several  
365 factors associated with anxiety and stress can be caused by the post-holiday period or by  
366 winter weather. In fact, very few compounds were found in the months following the summer  
367 (September to December).

368 On the other hand, in relation with the localization variation, it is interesting highlight that not  
369 was detected traces of some target compounds in Marseille, during the monitoring camping  
370 carried out in September 2012. Similarly, during the same sampling period performed in  
371 Montpellier area, some metabolites of VEN were only identified in the sample collected from  
372 lagoon (IM: sept-2012). This can be explained because this batch of mussels, after its  
373 purchase, had to be placed for several days in a lagoon in the area, before its distribution to  
374 the different sampling points studied. Thus, the results support the hypothesis of a higher  
375 contamination of the waters of the lagoon compared to marine waters. The lagoon is  
376 connected to the Mediterranean Sea and is the largest in the region of Languedoc-Roussillon.  
377 They receive inputs from various human activities, i.e. urban activities, industries, port  
378 activities and agriculture. Besides, the spa tourism is an important activity in that area, being  
379 the second thermal station in France and the first of the Mediterranean. Finally, note that no  
380 differences were observed when a same point was sampling at different levels in the water  
381 column (samples placed in the surface vs middle of the water column).

382  
383

## 384 **Conclusions**

385 This paper reports for the first time results on the presence of a highly prescribed  
386 antidepressant (venlafaxine) and some of its main transformation products in marine  
387 organisms. As part of this study, an analytical approach including QuEChERS extraction and  
388 analysis by LC-Orbitrap-MS system was developed. The method was validated according to  
389 the most demanding requirements regarding mass spectrometric confirmation and quality  
390 measurement criteria currently set by EU regulations, in order to ensure satisfactory positive  
391 results. The main advantages of the extraction protocol proposed in this study (QuEChERS)

392 are its economy, simplicity, and rapidity. Moreover, this approach allowed to obtained high  
393 recoveries even to polar compounds, which is a common characteristic of the metabolites.  
394 Venlafaxine and some of its sub-products were found in marine mussels at ultra-trace levels  
395 (ng/g dw) during the biomonitoring program carried out. The presence of target compounds  
396 varied depending on localization, the seasonal and on the population density of the area.

397 On the other hand, these organisms have proven to be a useful tool for monitoring of  
398 hydrophilic organic compounds from marine waters. The work provides additional broad-  
399 interest data regarding to knowledge of transformation products concentration levels in  
400 aquatic organisms, which not were previously informed. Finally, monitoring data indicated  
401 that the general population may be exposed to VEN and its metabolites, providing another  
402 possible exposure route and raising questions about human health consequences. To date,  
403 informations on PPCPs in aquatic organims indicate that an additional understanding their  
404 accumulation is necessary, in order to characterized ecological and human health risks of such  
405 substances in the environment. Although the initial results were positive, future experiments  
406 should be conducted on the bioaccumulation of VEN and its metabolites in marine mussels.

407

#### 408 **ACKNOWLEDGEMENTS**

409 The authors are very grateful for the financial support given by the Sanofi and the French  
410 Agence Nationale de la Recherche (Project PEPSEA). This work was conducted within the  
411 Chair Emerging Pollutants (Veolia-Hydrosiences). The authors also gratefully acknowledge  
412 IFREMER for assistance with mussel collection. M.J. Martínez Bueno wishes to thank UM1  
413 (University of Montpellier) for the postdoc grant.

414

415 **References**

416

417 (1) Focazio, M. J.; Kolpin, D. W.; Barnes, K. K.; Furlong, E. T.; Meyer, M. T.; Zaugg, S. D.;  
418 Barber, L. B.; Thurman, M. E. A national reconnaissance for pharmaceuticals and other  
419 organic wastewater contaminants in the United States - II) Untreated drinking water  
420 sources. *Sci. Total Environ.* **2008**, *402*, 201–216.

421 (2) Recommendation of the European parliament and of the council of 30 may 2002  
422 concerning the implementation of integrated coastal zone management in Europe  
423 (2002/413/EC) official journal of the European Communities 6.6.2002.

424 (3) Howell, S.R.; Husbands, G.E.M.; Scatina, G.A.; Sisenwine, S.F. Metabolic disposition of  
425 super (14)C-venlafaxine in mouse, rat, dog, rhesus monkey and man. *Xenobiotica* **1993**,  
426 *23*:349–359.

427 (4) Thomas, M.A.; Klaper, R.D. Psychoactive Pharmaceuticals Induce Fish Gene Expression  
428 Profiles Associated with Human Idiopathic Autism. *PLoS ONE* **2012**, *7*, 32917.  
429 doi:10.1371/journal.pone.0032917.

430 (5) Martínez Bueno, M.J.; Gómez, M.J.; Herrera, S.; Hernando, M.D.; Agüera, A.; Fernández-  
431 Alba, A.R. Occurrence and persistence of organic emerging contaminants and priority  
432 pollutants in five sewage treatment plants of Spain: Two years pilot survey monitoring.  
433 *Environ. Pollut.* **2012**, *164*, 267–273.

434 (6) Lajeunesse, A.; Gagnon, C.; Sauve, S. Determination of Basic Antidepressants and Their  
435 N-Desmethyl Metabolites in Raw Sewage and Wastewater Using Solid-Phase Extraction  
436 and Liquid Chromatography-Tandem Mass Spectrometry. *Anal. Chem.* **2008**, *80*, 5325–  
437 5333

438 (7) Rúa-Gómez, P.C.; Püttmann, W. Occurrence and removal of lidocaine, tramadol,  
439 venlafaxine, and their metabolites in German wastewater treatment plants. *Environ Sci*  
440 *Pollut Res.* **2012**, *19*, 689–699.

441 (8) Schultz, M.M.; Furlong, E.T.; Kolpin, D.W.; Werner, S.L.; Schoenfuss, H. L.; Barber,  
442 L.B.; Blazer, V.S.; Norris D.O.; Vajda, A.M. Antidepressant Pharmaceuticals in Two U.S.  
443 Effluent-Impacted Streams: Occurrence and Fate in Water and Sediment, and Selective  
444 Uptake in Fish Neural Tissue. *Environ. Sci. Technol.* **2010**, *44*, 1918–1925.

445 (9) Metcalfe, C.D.; Chu, S.; Judt, C.; Li, H.; Oakes, K.D.; Servos, M.R.; Andrews, D.M.  
446 Antidepressants and their metabolites in municipal wastewater, and downstream exposure  
447 in an urban watershed. *Environmental Toxicology and Chemistry*, **2010**, *29*, 79–89.

448 (10) de Jongh, C.M., Kooij, P.J.F.; de Voogt, P.; ter Laak, T.L. Screening and human health  
449 risk assessment of pharmaceuticals and their transformation products in Dutch surface  
450 waters and drinking water. *Science of the Total Environment* **2012**, *427-428*, 70–77.

451 (11) Valcárcel, Y.; González Alonso, S.; Rodríguez-Gil, J.L.; Gil, A.; Catalá, M. Detection of  
452 pharmaceutically active compounds in the rivers and tap water of the Madrid region  
453 (Spain) and potential ecotoxicological risk. *Chemosphere* **2011**, *84* (10), 1336–1348.

454 (12) Rúa-Gómez, P.C.; Püttmann, W. Impact of wastewater treatment plant discharge of  
455 lidocaine, tramadol, venlafaxine and their metabolites on the quality of surface waters and  
456 groundwater. *J. Environ. Monit.*, **2012**, *14*, 1391

457 (13) Martínez Bueno, M.J.; Hernando, M.D.; Agüera, A.; Fernández-Alba, A.R. Application  
458 of passive sampling devices for screening of micro-pollutants in marine aquaculture using  
459 LCMSMS. *Talanta* **2009**, *77*, 1518–1527.

460 (14) Zabiegala, B.; Kot-Wasik, A.; Urbanowicz, M.; Namiesnik, J. Passive sampling as a tool  
461 for obtaining reliable analytical information in environmental quality monitoring. *Anal.*  
462 *Bioanal. Chem.* **2010**, *396*, 273–279.

- 463 (15) Munaron, D.; Tapie, N.; Budzinski, H.; Andral, B.; Gonzalez, J.L. Pharmaceuticals,  
464 alkylphenols and pesticides in Mediterranean coastal waters: Results from a pilot survey  
465 using passive samplers. *Estuarine Coastal and Shelf Science*, **2012**, *114*, 82-92.
- 466 (16) E. Gomez, M. Bachelot, C. Boillot, D. Munaron, S. Chiron, C. Casellas and H. Fenet, H.  
467 Bioconcentration of two pharmaceuticals (benzodiazepines) and two personal care  
468 products (UV filters) in marine mussels (*Mytilus galloprovincialis*) under controlled  
469 laboratory conditions. *Environ. Sci. Pollut. Res.* **2012**, *19*, 2561–2569.
- 470 (17) Munsch, C.; Marchand, P.; Venisseau, A.; Veyrand, B.; Zendong, Z. Levels and trends  
471 of the emerging contaminants HBCDs (hexabromocyclododecanes) and PFCs  
472 (perfluorinated compounds) in marine shellfish along French coasts. *Chemosphere* **2013**,  
473 *91*, 233–240.
- 474 (18) [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656&loc=ec\\_rcs](http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656&loc=ec_rcs)
- 475 (19) Togundea, O.P.; Oakesb, K.D.; Servosb, M.R.; Pawliszyna, J. Optimization of solid  
476 phase microextraction for non-lethal in vivo determination of selected pharmaceuticals in  
477 fish muscle using liquid chromatography–mass spectrometry. *Journal of Chromatography*  
478 *A*, **2012**, *1261*, 99–106.
- 479 (20) Ramirez, A. J.; Brain, R. A.; Usenko, S.; Mottaleb, M. A.; O'Donnell, J. G.; Stahl, L. L.;  
480 Wathen, J. B.; Snyder, B. D.; Pitt, J. L.; Perez-Hurtado, P.; Dobbins, L. L.; Brooks, B. W.;  
481 Chambliss, C. K. Occurrence of pharmaceuticals and personal care products (PPCPs) in  
482 fish: Results of a national pilot study in the U.S. *Environ. Toxicol. Chem.* **2009**, *28*, 2587–  
483 2597.
- 484 (21) Commission Decision 2002/657/EC, Off. J. Eur. Commun. L221, **2002**, 8.
- 485 (22) SANCO/10684/2009. Method validation and Quality Control procedure for pesticides  
486 residues analysis in food and feed, **2010**. Document No. SANCO/10684/2009
- 487 (23) Martínez Bueno, M.J.; Boillot, C.; Fenet, H.; Chiron, S.; Casellas, C.; Gómez, E. Fast and  
488 Easy extraction combined with High Resolution-Mass Spectrometry for Residue Analysis  
489 of two Anticonvulsants and their transformation products in Marine Mussels. *Journal of*  
490 *Chromatography A*, **2013**, *in press*. doi: 10.1016/j.chroma.2013.06.071
- 491 (24) ISO/IEC/EN 17025. General Requirements for the Competence of Calibration and  
492 Testing Laboratories.
- 493 (25) Fernandez-Alba, A.R. In *Chromatographic–Mass Spectrometric Food Analysis for Trace*  
494 *Determination of Pesticide Residues*; Fernandez-Alba, A.R., Ed.; Comprehensive  
495 Analytical Chemistry, vol. XLIII, Elsevier, Amsterdam, 2004.
- 496 (26) Kellmann, M.; Muenster, H.; Zomer, P.; Mol, H. Full scan MS in comprehensive  
497 qualitative and quantitative residue analysis in food and feed matrices: How much  
498 resolving power is required? *J. Am. Soc. Mass Spectrom.* **2009**, *20*, 1464-1476.
- 499 (27) Nakamura, Y.; Yamamoto, H.; Sekizawa, J.; Kondo, T.; Hirai, N.; Tatarakazo, N. The  
500 effects of pH in Japanese medaka (*Oryzias latipes*): Acute toxicity in fish larvae and  
501 bioaccumulation in juvenile fish. *Chemosphere* **2008**, *70*, 865–873.
- 502 (28) Howell, S.R.; Husbands, G.E.M.; Scatina, G.A.; Sisenwine, S.F. Metabolic disposition of  
503 super(14)C-venlafaxine in mouse, rat, dog, rhesus monkey and man. *Xenobiotica* **1993**,  
504 *23*, 349–359.

- 505 (29) Klosterhaus, S.L. ; Grace, R. ; Hamilton, M.C. ; Yee, D. Method validation and  
506 reconnaissance of pharmaceuticals, personal care products, and alkylphenols in surface  
507 waters, sediments, and mussels in an urban estuary. *Environment International* **2013**, *54*,  
508 92–99
- 509 (30) Environmental Science Center of Syracuse Research Corporation (SRC), EPI Suite™  
510 Estimation Software, U.S. Environmental Protection Agency (EPA), 2001,  
511 <http://www.epa.gov/oppt/exposure/docs/episuitedi.htm> (accessed 20.02.2011).
- 512









513 **TABLES**

514

515

519

**Table 1.** Physicochemical properties of venlafaxine and its metabolites.

Analyte	Molecular structure	Molecular formula	CAS N°.	Molecular weight	Water solubility <sup>a</sup>	Log K <sub>ow</sub> <sup>b</sup>
NNDDODV		C <sub>14</sub> H <sub>21</sub> NO <sub>2</sub>	135308-76-8	235.1566	-	-
NODDV		C <sub>15</sub> H <sub>22</sub> NO <sub>2</sub>	135308-74-6	249.1723	-	-
ODV		C <sub>16</sub> H <sub>25</sub> NO <sub>2</sub>	93413-62-8	263.1879	3670	2.72
NNDDV		C <sub>15</sub> H <sub>23</sub> NO <sub>2</sub>	93413-77-5	249.1723	-	-
NDV		C <sub>16</sub> H <sub>25</sub> NO <sub>2</sub>	149289-30-5	263.1879	485.2	3.07
VEN		C <sub>17</sub> H <sub>27</sub> NO <sub>2</sub>	99300-78-4	277.2036	266.7	3.28

518

519

520

521

<sup>a,b</sup> Predicted data cited from chemspider.com, which is generated using U.S. Environmental Protection Agency's EPI Suite™ (KOWWIN v1.67 estimate). Data of water solubility at 25°C (mg/L).

522 **Table 2.** Analytical performance data for each target compound studied by LC-Orbitrap-MS method.  
 523

<b>Compound</b>	<b>Matrix Effect</b>	<b>Inter/intra-day (R.S.D, %)</b>	<b>Rec. % (<math>\pm \sigma</math>)</b>	<b>LOQ (ng/g)</b>	<b>LOD (ng/g)</b>	<b>MQL (ng/g)</b>	<b>MDL (ng/g)</b>
<b>NNDDODV</b>	16	6/8	55 (9) <sup>a</sup> 70 (8) <sup>b</sup>	0.7	0.2	3.6	1.1
<b>NODDV</b>	-31	5/14	78 (5) <sup>a</sup> 70 (3) <sup>b</sup>	0.6	0.2	3.0	1.0
<b>ODV</b>	-30	4/13	78 (5) <sup>a</sup> 79 (3) <sup>b</sup>	0.7	0.2	3.5	1.1
<b>NNDDV</b>	19	4/3	61 (6) <sup>a</sup> 61 (2) <sup>b</sup>	0.8	0.3	3.8	1.5
<b>NDV</b>	4	2/5	76 (3) <sup>a</sup> 71 (2) <sup>b</sup>	0.5	0.1	2.5	0.5
<b>VEN</b>	8	1/3	88 (3) <sup>a</sup> 80 (4) <sup>b</sup>	0.5	0.1	2.5	0.5

524 **Inter/intra-day:** repeatability/reproducibility of the instrumental method (R.S.D, %); R.S.D:  
 525 relative standard deviation; **Rec:** recovery average values obtained at two spiked levels (a) and (b),  
 526 5 and 50 ng/g, respectively;  $\sigma$ : dispersion from the average recovery values; **LOQ:** limit of  
 527 quantification; **LOD:** limit of detection; **MQL:** method quantification limit; **MDL:** method  
 528 detection limit.  
 529  
 530

531 **Table 3.** Concentration of venlafaxine and its metabolites (ng/g dw) in 34 samples of marine mussel  
 532 samples (*M. galloprovincialis*) collected during the biomonitoring program carried out.

533  
 534  
 535

Sampling Point	Exposure period (day/month)	NNDDODV (ng/g dw)	NODDV (ng/g dw)	ODV (ng/g dw)	NNDDV (ng/g dw)	NDV (ng/g dw)	VEN (ng/g dw)
<b>Montpellier</b>							
Jan-2011	To	/	/	/	/	/	/
	IM 25/01-22/03	/	/	/	/	<MQL	/
	IM 25/01-26/05	/	/	/	/	/	/
	N 25/01-22/03	/	3.0	/	/	2.5	/
	E 25/01-22/03	/	/	<MDL	/	2.9	<MQL
	W 25/01-22/03	/	3.5	/	/	3.0	/
Mars-2011	To	/	/	/	/	/	/
	IM 22/03-24/05	/	/	/	/	/	/
	N 22/03-24/05	/	/	/	/	/	/
	E 22/03-24/05	/	/	3.7	/	<MQL	<MQL
	W 22/03-24/05	/	/	/	/	/	/
April-2012	To	/	/	/	/	/	/
	IM 12/04-21/06	/	/	/	/	/	/
	N 12/04-21/06	/	2.5	/	/	/	/
	E 12/04-21/06	/	/	/	/	2.5	2.7
	W 12/04-21/06	/	/	/	/	/	/
Sept-2012	IM 02/09-06/09	/	/	/	3.8	<MDL	<MQL
	Ref 06/09-03/12	/	/	/	/	/	/
	N 06/09-03/12	/	/	/	/	/	/
	E 06/09-03/12	/	/	/	/	/	/
	W 06/09-loss	n.a	n.a	n.a	n.a	n.a	n.a
Dec-2012/13	Ref 03/12-05/03	/	/	/	/	/	/
	N 03/12-05/03	/	/	/	/	/	/
	E 03/12-05/03	/	/	/	/	/	/
<b>Marseille</b>							
Sept-2012	To	/	/	/	/	/	/
	Ref <sub>s</sub> 09/09-05/12	/	/	/	/	/	/
	Ref <sub>m</sub> 09/09-05/12	/	/	/	/	/	/
	N <sub>s</sub> 10/09-05/12	/	/	/	/	/	/
	N <sub>m</sub> 10/09-05/12	/	/	/	/	/	/
	E <sub>s</sub> 10/09-05/12	/	/	/	/	/	/
	E <sub>m</sub> 10/09-05/12	/	/	/	/	/	/
<b>Supermarket</b>							
June-2011	#1 30/06/2011	/	/	/	/	/	/
Sept-2011	#2 15/09/11	/	/	/	/	/	/
Nov-2012	#3 10/11/12	/	/	/	/	/	/
Jan-2013	#4 19/01/12	/	/	/	/	/	/

536

537 **To:** before exposure; **IM:** lagoon point; **N:** north emissary point; **E:** east emissary point; **W:** west emissary point;  
 538 **Ref:** reference zone or production cultures; **X<sub>s</sub>:** samples placed on the surface of the water column; **X<sub>m</sub>:** samples  
 539 placed in the middle of the water column; **n.a:** data not available, sample loss; **<MQL/MDL:** below to method  
 540 quantification/detection limit (ng/g dw).


541

542 **FIGURES**


543 **Figure 1.** Chromatogram, precursor and product ion mass spectrum obtained in MS and MS/MS mode  
544 for each target analyte using a fragmentation energy of 15 eV at 1 ng/g in a mussel extract.

545 **Figure 2.** Example of the identification of N,N-Didesmethylvenlafaxine (NNDDV), a metabolite  
546 of antidepressant venlafaxine in a marine mussel sample, based on MS and MS/MS  
547 information.

## Graphical Abstracts



**Figure 1.** Chromatogram, precursor and product ion mass spectrum obtained in MS and MS/MS mode for each target analyte using a fragmentation energy of 15 eV at 1ng/g in a mussel extract.



**Figure 2.** Example of the identification of N,N-Didesmethylvenlafaxine (NNDDV), a metabolite of antidepressant venlafaxine in a marine mussel sample, based on MS and MS/MS information.

